Search clinical trials for: BI 207127: 24-week treatment

Total 278 results

Boehringer Ingelheim

Completed

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Hepatitis C, Chronic

United States, Australia, Belgium, Canada, France, Germany, Greece, Italy, New Zealand, Portugal, Spain, United Kingdom
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

Hepatitis C, Chronic

United States, Australia, Austria, France, Germany, New Zealand, Portugal, Romania, Spain, Switzerland
Boehringer Ingelheim

Completed

Bioavailability of 3 Different Formulations of BI 207127 in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

Hepatitis C, Chronic

France, Germany, Switzerland
Boehringer Ingelheim

Terminated

Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired Patients

Renal Insufficiency

Germany
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Single Rising Oral Doses of BI 207127 NA as Powder in the Bottle in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Terminated

Effect of Food and Increased Gastric pH Value on Bioavailability of a Single Dose of BI 207127 in Healthy Caucasian and Japanese Subjects

Healthy

Germany
Presidio Pharmaceuticals, Inc.
Boehringer Ingelheim

Completed

Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

Chronic Hepatitis C

United States
Eunice Kennedy Shriver National Institute of Child...
National Institute on Aging (NIA)

Completed

Yoga for Kyphosis Trial

Kyphosis

United States
Boehringer Ingelheim

Completed

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers

Healthy

United States
Boehringer Ingelheim

Completed

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

Hepatitis C, Chronic

United States, Germany, Spain, United Kingdom
Boehringer Ingelheim

Completed

Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients

Hepatitis C, Chronic
Aelix Therapeutics

Completed

Safety and Immunogenicity Study of DNA.HTI, MVA.HTI and ChAdOx1.HTI in HIV-1-positive Patients (AELIX-002)

HIV

Spain
Boehringer Ingelheim

Completed

IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

Hepatitis C, Chronic

United States, Austria, Canada, France, Germany, Hungary, Ireland, Italy, Netherlands, Portugal, Romania, Russian Federation, Spain, United Kingdom
German Breast Group
Novartis

Completed

Dose EScalation Induction of EvERolimus (Desiree)

Breast Cancer | Hormone Receptor Positive Tumor

Germany
University of Alabama at Birmingham
University of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaborators

Completed

Complementary and Alternative Medicine for Urological Symptoms(CAMUS) (CAMUS)

Urological

United States, Canada
Intermountain Health Care, Inc.
Intermountain Research and Medical Foundation

Completed

The Fasting II Study

Metabolic Diseases | Diabetes

United States
Boehringer Ingelheim

Completed

Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.

Healthy

Germany
Boehringer Ingelheim

Completed

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Japan
Asahi Kasei Pharma Corporation

Recruiting

Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

China
University of Calgary
Canadian Institutes of Health Research (CIHR)

Completed

Renewing Caregiver Health and Well-being Through Exercise (RECHARGE)

Family Caregivers

Canada
Boehringer Ingelheim

Completed

A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 1467335 Tablet and Oral Solution, and Food Effect on Tablet in Healthy Male Subjects

Healthy Volunteers

Germany
Boehringer Ingelheim

Withdrawn

Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients

Hepatitis C, Chronic

Australia, Spain, Sweden
Association Francaise pour la Recherche Thermale
University Hospital, Grenoble; Floralis

Withdrawn

SPA Therapy in the Treatment of Sleep Apnea Syndrome (THERMA-SAS)

Obstructive Sleep Apnea Syndrome | Chronic Venous Insufficiency

France
Merck Sharp & Dohme LLC

Completed

Comparative Study of Ertapenem Versus Another Antibiotic in the Treatment of Diabetic Foot Infections in Adults (0826-034)

Foot Infections in Diabetic Patients
University Hospital, Ghent
Merck Sharp & Dohme LLC

Recruiting

Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade (SPARTACUS)

Peripheral Spondyloarthritis

Belgium
University of Salford
Northern Care Alliance NHS Foundation Trust

Unknown

The Role of Arthrogenic Muscular Inhibition in Patellofemoral Pain and the Response to an Exercise Programme (PFP-Inhibit)

Patellofemoral Pain | Anterior Knee Pain | PFP

United Kingdom
ASIS Corporation

Unknown

ASIS for Enbrel in Plaque Psoriasis (ASISinPP)

Plaque Psoriasis.

United States
New Mexico VA Healthcare System

Completed

Effectiveness of Cognitive, Exposure, and Skills Group Manualized Treatments in Operations Iraqi (OIF)/Operation Enduring Freedom (OEF) Female Veterans

Post Traumatic Stress Disorder

United States
Assistance Publique - Hôpitaux de Paris

Completed

Effectiveness of a 24 Hour Phone Line on the Rate of Suicide Attempts in Borderline Patients

Borderline Personality Disorder

France
ASIS Corporation

Unknown

ASIS for GAMMAGARD in Primary Immunodeficiency (ASISinPI)

Primary Immunodeficiency

United States
National Taiwan University Hospital

Unknown

NUC in Preventing HBV Reactivation in HCV/HBV Co-infected Patients Receiving DAA for CHC

HBV/HCV Co-infection

Taiwan
IrsiCaixa
Hospital Clinic of Barcelona; University of Oxford; Fundación FLS de Lucha Contra... and other collaborators

Completed

Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals

HIV

Spain
National Taiwan University Hospital
National Science Council, Taiwan

Unknown

Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B

Hepatitis B, Chronic

Taiwan
Utrecht Institute for Pharmaceutical Sciences
UCB Pharma

Terminated

Seasonal Allergic Rhinitis and Driving Ability

Seasonal Allergic Rhinitis

Netherlands
Mitsubishi Tanabe Pharma Corporation
Toray Industries, Inc

Completed

Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)

Chronic Hepatitis C(CHC)

Japan
Mediprobe Research Inc.
Emblation Limited

Recruiting

Pilot Study of Swift Microwave Device for Onychomycosis

Onychomycosis of Toenail

Canada
Assistance Publique - Hôpitaux de Paris

Completed

Liberalization of Visiting Policies in ICU for Reducing High Risk of Post-traumatic Stress Disorder (OPEN-UNIT)

PTSD in Family Members of ICU Patients
Universidad de Granada
University of Pittsburgh; University Hospital Virgen de las Nieves; Instituto... and other collaborators

Completed

Active Gains in Brain Using Exercise During Aging (AGUEDA)

Healthy | Cognitive Function 1, Social

Spain
The University of Hong Kong

Completed

Effects of SUDOKU Mind Activation & Revitalizing Training on Cognitive Function in People With Mild Cognitive Impairment (SMART)

Mild Cognitive Impairment

Hong Kong
Medical University of Graz

Completed

Image Guided Adaptive Radiotherapy in the Head-and-neck Region (BART)

Head and Neck Neoplasms
Ipsen

Completed

Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly

Acromegaly

Germany
Heidelberg University
Wala GmbH

Completed

Treating Climacteric Symptoms With a Complex Homeopathic Remedy

Depression | Anxiety Disorders | Menopause

Germany
University of Birmingham
BUPA Foundation

Unknown

"Step by Step": A Feasibility Study of the Promotion of Lunchtime Walking to Increase Physical Activity and Improve Mental Well-being in Sedentary Employees

Exercise | Sedentary

United Kingdom
Merck Sharp & Dohme LLC

Terminated

A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)

Adenomatous Polyposis Coli
University of Michigan
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

SafERteens M-Coach

Alcohol Drinking | Violence

United States

3

Subscribe